Financial PerformanceTSLX reported adjusted NOI of $0.57, ahead of the $0.56 estimate, primarily on an increase in velocity-related revenue.
Investment GainsTSLX is likely to recognize a gain from its investment in Arrowhead Pharmaceuticals, as the company announced a licensing and collaboration agreement that will likely result in a positive outcome.
Investment StrategyTSLX continues to deliver strong risk-adjusted returns, which justifies its premium valuation.